GlassScriptPhysician profile
Melody L Matej
NPI 1093292096
$8,402.44
in general payments reported to CMS, 2019-2025
41 companies · $2,718 in 2025
The $2,718 reported for 2025 was more than what 97% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $4.06 · 2022: $661 · 2023: $2,911 · 2024: $2,109 · 2025: $2,718.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,575 · Education: $163.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,574.51 |
| Education | $162.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $819.63 | 2022-2025 | Airsupra, Farxiga, Breztri |
| Axsome Therapeutics, INC. | $794.81 | 2024-2025 | Auvelity |
| Abbvie INC. | $720.63 | 2022-2025 | |
| Amgen INC. | $629.68 | 2022-2025 | Repatha, Otezla, Krystexxa |
| Lilly USA, LLC | $572.72 | 2022-2025 | Mounjaro, Zepbound, Jardiance |
| Abbott Laboratories | $568.34 | 2023-2025 | Freestyle Libre 3, Freestyle Libre |
| Astellas Pharma US INC | $562.17 | 2022-2025 | Veozah, Myrbetriq |
| Novo Nordisk INC | $319.82 | 2023-2025 | Rybelsus, Ozempic, Wegovy |
| Exact Sciences Corporation | $315.24 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Idorsia Pharmaceuticals US INC | $279.78 | 2022-2024 | Quviviq |
| Pfizer INC. | $264.62 | 2023-2025 | |
| Glaxosmithkline, LLC. | $234.45 | 2022-2025 | Shingrix, Trelegy Ellipta, Arexvy |
| Genzyme Corporation | $199.96 | 2023 | |
| Biohaven Pharmaceutical Holding Company LTD. | $159.98 | 2022 | |
| Medtronic, INC. | $155.82 | 2022-2024 | Micra, Intellis Adaptivestim |
Show all 41 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kyowa Kirin, INC. | $139.51 | 2023 | |
| Kowa Pharmaceuticals America, INC. | $138.10 | 2023-2025 | Zoryve, Livalo, Seglentis |
| Sanofi-Aventis U.S. LLC | $133.14 | 2024-2025 | |
| Janssen Pharmaceuticals, INC | $131.91 | 2022-2024 | Spravato, Xarelto |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $129.53 | 2023-2025 | Xifaxan |
| Cardiovascular Systems INC. | $126.01 | 2023 | Diamondback Peripheral |
| Corcept Therapeutics | $119.59 | 2025 | Korlym |
| Grifols USA, LLC | $115.75 | 2025 | Prolastin-C Liquid |
| Sumitomo Pharma America, INC. | $104.69 | 2023 | Gemtesa |
| Exeltis, USA INC. | $103.35 | 2025 | Slynd, Twirla |
| Merck Sharp & Dohme LLC | $98.74 | 2022-2024 | Gardasil, Gardasil 9, Capvaxive |
| Optinose US, INC. | $81.71 | 2024 | |
| Boston Scientific Corporation | $49.45 | 2025 | Wavewriter Alpha Prime 16, Watchman Flx |
| Boehringer Ingelheim Pharmaceuticals, INC. | $49.19 | 2023-2025 | |
| Dexcom, INC. | $44.99 | 2024-2025 | Dexcom G6 Transmitter |
| Renalytix Ai, INC. | $38.85 | 2023-2024 | Kidneyintelx Blood Collection Convenience Kit |
| Cranial Technologies, INC | $38.42 | 2024-2025 | Doc Band |
| Bayer Healthcare Pharmaceuticals INC. | $32.53 | 2025 | |
| Currax Pharmaceuticals LLC | $28.14 | 2023 | Contrave |
| Cipher Pharmaceuticals US LLC | $22.48 | 2025 | Natroba, Spinosad |
| Ani Pharmaceuticals, INC. | $17.46 | 2025 | Purified Cortrophin Gel |
| Stryker Corporation | $16.35 | 2024 | Triathlon, Mako |
| Phadia US INC. | $15.48 | 2022 | |
| Lexicon Pharmaceuticals, INC. | $13.11 | 2024 | |
| Arbor Pharmaceuticals, INC. | $12.25 | 2022 | |
| Genentech USA, INC. | $4.06 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Melody Matej listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.